A phase 3, double-blind, randomized placebo-controlled efficacy and safety study of abiraterone acetate in chemotherapynaïve patients with mCRPC in China, Malaysia, Thailand and Russia
Dingwei Yea, Yiran Huangb, Fangjian Zhouc, Keji Xied, Vsevolod Matveeve, Changling Lif, Boris Alexeevg, Ye Tianh, Mingxing Qiui, Hanzhong Lij, Tie Zhouk, Peter De Porrel, Margaret Yum, Vahid Nainim, Hongchuan Liangn, Zhuli Wun, Yinghao Sunk
a Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China; b Department of Urology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China; c Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China; d Guangzhou First Municipal People's Hospital, Guangzhou, Guangdong, China; e Department of Urology, Russian Academy of Medical Sciences, Moscow, Russia; f Department of Urology, Cancer Institute (Hospital), Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China; g Department of Oncology, Moscow Oncology Research Institute, Moscow, Russia; h Department of Stomatology, Beijing Friendship Hospital, Capital Medical University, Beijing, China; i Department of Urology, Sichuan Academy of Medical Science & Sichuan Provincial People's Hospital, Chengdu, Sichuan, China; j Department of Oncology, Peking Union Medical College Hospital, Beijing, China; k Department of Urology, Changhai Hospital, Second Military Medical University, Shanghai, China; l Department of Oncology, Janssen Research & Development, Beerse, Belgium; m Department of Medical Oncology, Janssen Research & Development, San Diego, CA, USA; n Department of Urology, Janssen Research & Development, Beijing, China
A phase 3, double-blind, randomized placebo-controlled efficacy and safety study of abiraterone acetate in chemotherapynaïve patients with mCRPC in China, Malaysia, Thailand and Russia
Dingwei Yea, Yiran Huangb, Fangjian Zhouc, Keji Xied, Vsevolod Matveeve, Changling Lif, Boris Alexeevg, Ye Tianh, Mingxing Qiui, Hanzhong Lij, Tie Zhouk, Peter De Porrel, Margaret Yum, Vahid Nainim, Hongchuan Liangn, Zhuli Wun, Yinghao Sunk
a Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China; b Department of Urology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China; c Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China; d Guangzhou First Municipal People's Hospital, Guangzhou, Guangdong, China; e Department of Urology, Russian Academy of Medical Sciences, Moscow, Russia; f Department of Urology, Cancer Institute (Hospital), Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China; g Department of Oncology, Moscow Oncology Research Institute, Moscow, Russia; h Department of Stomatology, Beijing Friendship Hospital, Capital Medical University, Beijing, China; i Department of Urology, Sichuan Academy of Medical Science & Sichuan Provincial People's Hospital, Chengdu, Sichuan, China; j Department of Oncology, Peking Union Medical College Hospital, Beijing, China; k Department of Urology, Changhai Hospital, Second Military Medical University, Shanghai, China; l Department of Oncology, Janssen Research & Development, Beerse, Belgium; m Department of Medical Oncology, Janssen Research & Development, San Diego, CA, USA; n Department of Urology, Janssen Research & Development, Beijing, China
摘要 Objective: This double-blind, placebo-controlled phase 3 study was designed to compare efficacy and safety of abiraterone acetate+prednisone (abiraterone) to prednisone alone in chemotherapy-naïve, asymptomatic or mildly symptomatic metastatic castrationresistant prostate cancer (mCRPC) patients from China, Malaysia, Thailand and Russia. Methods: Adult chemotherapy-naïve patients with confirmed prostate adenocarcinoma, Eastern Cooperative Oncology Group (ECOG) performance status (PS) grade 0-1, ongoing androgen deprivation (serum testosterone <50 ng/dL) with prostate specific antigen (PSA) or radiographic progression were randomized to receive abiraterone acetate (1000 mg, QD)+prednisone (5 mg, BID) or placebo+prednisone (5 mg, BID), until disease progression, unacceptable toxicity or consent withdrawal. Primary endpoint was improvements in time to PSA progression (TTPP). Results: Totally, 313 patients were randomized (abiraterone:n=157; prednisone:n=156); and baseline characteristics were balanced. At clinical cut-off (median follow-up time:3.9 months), 80% patients received treatment (abiraterone:n=138, prednisone:n=112). Median time to PSA progression was not reached with abiraterone versus 3.8 months for prednisone, attaining 58% reduction in PSA progression risk (HR=0.418; p<0.0001). Abirateronetreated patients had higher confirmed PSA response rate (50% vs. 21%; relative odds=2.4; p<0.0001) and were 5 times more likely to achieve radiographic response than prednisonetreated patients (22.9% vs. 4.8%, p=0.0369). Median survival was not reached. Most common (10% abiraterone vs. prednisone-treated) adverse events:bone pain (7% vs. 14%), pain in extremity (6% vs. 12%), arthralgia (10% vs. 8%), back pain (7% vs. 11%), and hypertension (15% vs. 14%). Conclusion: Interim analysis confirmed favorable benefit-to-risk ratio of abiraterone in chemotherapy-naïve men with mCRPC, consistent with global study, thus supporting use of abiraterone in this patient population.
Abstract: Objective: This double-blind, placebo-controlled phase 3 study was designed to compare efficacy and safety of abiraterone acetate+prednisone (abiraterone) to prednisone alone in chemotherapy-naïve, asymptomatic or mildly symptomatic metastatic castrationresistant prostate cancer (mCRPC) patients from China, Malaysia, Thailand and Russia. Methods: Adult chemotherapy-naïve patients with confirmed prostate adenocarcinoma, Eastern Cooperative Oncology Group (ECOG) performance status (PS) grade 0-1, ongoing androgen deprivation (serum testosterone <50 ng/dL) with prostate specific antigen (PSA) or radiographic progression were randomized to receive abiraterone acetate (1000 mg, QD)+prednisone (5 mg, BID) or placebo+prednisone (5 mg, BID), until disease progression, unacceptable toxicity or consent withdrawal. Primary endpoint was improvements in time to PSA progression (TTPP). Results: Totally, 313 patients were randomized (abiraterone:n=157; prednisone:n=156); and baseline characteristics were balanced. At clinical cut-off (median follow-up time:3.9 months), 80% patients received treatment (abiraterone:n=138, prednisone:n=112). Median time to PSA progression was not reached with abiraterone versus 3.8 months for prednisone, attaining 58% reduction in PSA progression risk (HR=0.418; p<0.0001). Abirateronetreated patients had higher confirmed PSA response rate (50% vs. 21%; relative odds=2.4; p<0.0001) and were 5 times more likely to achieve radiographic response than prednisonetreated patients (22.9% vs. 4.8%, p=0.0369). Median survival was not reached. Most common (10% abiraterone vs. prednisone-treated) adverse events:bone pain (7% vs. 14%), pain in extremity (6% vs. 12%), arthralgia (10% vs. 8%), back pain (7% vs. 11%), and hypertension (15% vs. 14%). Conclusion: Interim analysis confirmed favorable benefit-to-risk ratio of abiraterone in chemotherapy-naïve men with mCRPC, consistent with global study, thus supporting use of abiraterone in this patient population.
Dingwei Ye, Yiran Huang, Fangjian Zhou, Keji Xie, Vsevolod Matveev, Changling Li, Boris Alexeev, Ye Tian, Mingxing Qiu, Hanzhong Li, Tie Zhou, Peter De Porre, Margaret Yu, Vahid Naini, Hongchuan Liang, Zhuli Wu, Yinghao Sun. A phase 3, double-blind, randomized placebo-controlled efficacy and safety study of abiraterone acetate in chemotherapynaïve patients with mCRPC in China, Malaysia, Thailand and Russia[J]. Asian Journal of Urology, 2017, 4(2): 75-85.
Dingwei Ye, Yiran Huang, Fangjian Zhou, Keji Xie, Vsevolod Matveev, Changling Li, Boris Alexeev, Ye Tian, Mingxing Qiu, Hanzhong Li, Tie Zhou, Peter De Porre, Margaret Yu, Vahid Naini, Hongchuan Liang, Zhuli Wu, Yinghao Sun. A phase 3, double-blind, randomized placebo-controlled efficacy and safety study of abiraterone acetate in chemotherapynaïve patients with mCRPC in China, Malaysia, Thailand and Russia. Asian Journal of Urology, 2017, 4(2): 75-85.
[1] Cullen J, Elsamanoudi S, Brassell SA, Chen Y, Colombo M, Srivastava A, et al. The burden of prostate cancer in Asian nations. J Carcinog 2012;11:7. [2] Wang YC, Wei LJ, Liu JT, Li SX, Wang QS. Comparison of cancer incidence between China and the USA. Cancer Biol Med 2012; 9:128-32. [3] GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012. International Agency for Research in Cancer, World Health Organisation; 2012[20 Oct 2014] . Available from: http://globocan.iarc.fr/Pages/fact_sheets. [4] Hoedemaeker RF, Rietbergen JB, Kranse R, Schroder FH, van der Kwast TH. Histopathological prostate cancer characteristics at radical prostatectomy after population based screening. J Urol 2000;164:411-5. [5] Peyromaure M, Debre B, Mao K, Zhang G, Wang Y, Sun Z, et al. Management of prostate cancer in China: a multicenter report of 6 institutions. J Urol 2005;174:1794-7. [6] Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, et al. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 2014;65:467-79. [7] Fizazi K, Scher HI, Molina A, Logothetis CJ, Chi KN, Jones RJ, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 2012;13:983-92. [8] Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, et al. Abiraterone inmetastatic prostate cancerwithout previous chemotherapy. N Engl J Med 2012;368:138-48. [9] Bubley GJ, Carducci M, Dahut W, Dawson N, Daliani D, Eisenberger M, et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 1999;17:3461-7. [10] Sun Y, Zou Q, Sun Z, Li C, Du C, Chen Z, et al. Abiraterone acetate for metastatic castration-resistant prostate cancer after docetaxel failure: a randomized, double-blind, placebocontrolled phase 3 bridging study. Int J Urol 2016;23:404-11. [11] Matsubara N, Uemura H, Satoh T, Suzuki H, Nishiyama T, Uemura H, et al. A phase 2 trial of abiraterone acetate in Japanese men with metastatic castration-resistant prostate cancer and without prior chemotherapy (JPN-201 study). Jpn J Cancer Res 2014;44:1216-26. [12] Ryan CJ, Shah S, Efstathiou E, Smith MR, Taplin ME, Bubley GJ, et al. Phase II study of abiraterone acetate in chemotherapynaive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response. Clin Cancer Res 2011;17:4854-61. [13] Kantoff PW, Schuetz TJ, Blumenstein BA, Glode LM, Bilhartz DL, Wyand M, et al. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSAtargeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol 2010;28:1099-105.
Christopher Hartman, Nikhil Gupta, David Leavitt, David Hoenig, Zeph Okeke, Arthur Smith. Advances in percutaneous stone surgery[J]. Asian Journal of Urology, 2015, 2(1): 26
-32
.
